Most clinical studies have reported a complete and sustained molecular response in 35% of MPN patients after IFN administration [11,15], but there is currently no clinical data on the potential side effects of IFN on hemostasis. The gene discussed is IFNA1; the disease is myeloproliferative neoplasm.